CDMO News
BrainStorm Taps Minaris Advanced Therapies for NurOwn® Phase 3b Trial Manufacturing
BrainStorm Cell Therapeutics Inc. has entered a strategic collaboration with Minaris Advanced Therapies, signing a Letter of Intent to manufacture NurOwn® for its planned Phase 3b clinical trial. Minaris, a global CDMO with a focus on cell and gene therapies, will
28 May 2025
Stay ahead of trends and best practices
